Results presented by Avidity of interim data from its Phase 1/2 clinical trial in FSHD were all the buzz at this year’s International Research Congress and FSHD Connect conference. We also wrote about it on our blog. If you missed those meeting, you could catch it in our FSHD University webinar on June 20 (World FSHD Day!) presented by Jeffrey Statland, MD, and the Avidity team. Previously referred to as AOC 1020, Avidity announced the drug’s new approved international nonproprietary name, delpacibart braxlosiran, a real tongue-twister mercifully abbreviated as del-brax. Watch the video above. Slides are available to download here:
I have been able to completely regain my strength and fully recover from bilateral Scapulo Thoracic Fusions with medical cannabis. See my results on Facebook with Cannabis and Facio Scapulo Humeral Muscular Dystrophy, Minnesota. I don’t trust any of the clinical trials at all.
See my results on Facebook with Cannabis and Facio Scapulo Humeral Muscular Dystrophy, Minnesota. I don’t trust any of the clinical trials at all. Cannabis is safer and more effective than anything Biopharma is trying to push…
Del-Brad looks really promising. How do you get in studies. I am 77. Just found out I have FSHD